Vektor Medical Strengthens Leadership Team to Accelerate Commercial Growth and Market Expansion

SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced key leadership appointments to support commercial expansion and market entry initiatives. Michael Andersen has joined the company as Vice President, Sales, and Mihir Naik has been promoted to Vice President, Quality Assurance and Regulatory Affairs. These key moves position Vektor for rapid growth following its recently oversubscribed $25M Series A funding round.

“The expansion of our leadership team comes at a pivotal moment as we advance commercialization and prepare to enter new markets.” — Rob Krummen, CEO

Share

“The expansion of our leadership team comes at a pivotal moment as we advance commercialization and prepare to enter new markets; we must have the right leadership in place to execute our strategy,” said Rob Krummen, CEO of Vektor Medical. “Mike brings the expertise and experience to continue to expand vMap adoption among electrophysiologists, while Mihir’s leadership ensures we maintain the highest regulatory and quality standards as we grow. Their leadership is instrumental as we work to deliver on our mission to transform arrhythmia care. I look forward to sharing more about our progress and vision during my presentation at LSI this week.”

Michael Andersen, VP, Sales

Michael Andersen brings more than 20 years of commercial leadership experience in electrophysiology and medtech, with a strong track record of market development, sales execution, and strategic growth. Previously, he held senior roles at Hillrom, Abbott, and St. Jude Medical, where he successfully launched and expanded sales of advanced electrophysiology solutions. His expertise will be key in driving the adoption of vMap and accelerating revenue growth as Vektor expands its market presence.

Mihir Naik, VP, Quality Assurance and Regulatory Affairs

Mihir Naik has been promoted to Vice President, Quality Assurance and Regulatory Affairs, reinforcing Vektor’s unwavering commitment to patient safety, quality and regulatory excellence. Since joining the company, Mihir has played a key role in ensuring FDA compliance, a robust quality and compliance framework that supports commercial success while meeting global industry standards.

Corporate Update at LSI USA

CEO Rob Krummen will present a corporate update at LSI USA in Dana Point, California, on March 19 at 1:45 PM PST. The presentation will cover Vektor Medical’s strengthened leadership, commercial momentum, and commitment to innovation – fueled by the $25M Series A funding round, led by TVM Biosciences and Solas Bioventures. It will also provide insights into our future strategies and plans for vMap adoption and market expansion.

For more information on Vektor Medical and vMap, visit www.vektormedical.com and connect on LinkedIn and X.

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com.